|
1.) Xenova (XEN) shares have fallen from a high of 120p earlier this year to close at 49.5p this week. The acquisition last month of Cantab Pharmaceuticals (LSE: CTB.L - news) may have confused the market, but the fact remains that the drug pipeline has been significantly widened. Xenova`s lead product is an anti-cancer drug that could assist patients who develop resistance to chemotherapy. Development is at early stages and nothing is certain, but the drug might be a blockbuster. Long-awaited news on a joint venture partner could come within months. Brave investors may want to have a punt ahead of any announcement. 2.) The Sunday Telegraph Xenova [UK:XEN]. "Long-awaited news on a joint venture partner could come within months. Bio-tech firms should be avoided by widows and orphans but brave investors may want to have a punt ahead of any announcement. Buy" 3.) Monday April 23, 07:33 AM MARKETS-BRITAIN-STOCKTIPS =4 LONDON Marks & Spencer (LSE: MKS.L - news) Sell Xenova Group (LSE: XEN.L - news) Buy Ultimate Leisure (LSE: ULG.L - news) Worth tucking away Wolverhampton & Dudley Hold Photo-Me International (LSE: PHTM.L - news) Buy IQ-Ludorum (LSE: IQL.L - news) Buy |
|
| aus der Diskussion: | XENOVA - DISKUSSIONS-THREAD Nr. 2 (Stand: 06.11.2000) |
| Autor (Datum des Eintrages): | Panospana (24.04.01 23:45:48) |
| Beitrag: | 52 von 275 (ID:3381154) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |